[Federal Register Volume 85, Number 161 (Wednesday, August 19, 2020)]
[Notices]
[Page 51033]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-18161]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Lead Exposure and Prevention Advisory Committee (LEPAC)

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice of meeting.

-----------------------------------------------------------------------

SUMMARY: In accordance with the Federal Advisory Committee Act, the CDC 
announces the following meeting for the Lead Exposure and Prevention 
Advisory Committee (LEPAC). This meeting is open to the public by 
teleconference but advance registration by October 16, 2020 is needed 
to receive the information to join the meeting. The registration link 
is https://rossstrategic.zoom.us/webinar/register/WN_QsgX-UlJS02mWW8Kn8SUmg. The public comment period is scheduled on October 
30, 2020 from 1:30 p.m. until 1:45 p.m. Individuals wishing to make a 
comment during the public comment period, please email your name, 
organization, and phone number by October 16, 2020 to [email protected].

DATES: The meeting will be held on October 30, 2020, from 9:00 a.m. to 
4:30 p.m., EDT.

ADDRESSES: Register in advance at https://rossstrategic.zoom.us/webinar/register/WN_QsgX-UlJS02mWW8Kn8SUmg to receive information to 
join the meeting.

FOR FURTHER INFORMATION CONTACT: Ms. Perri Ruckart, M.P.H., Designated 
Federal Officer, National Center for Environmental Health, CDC, 4770 
Buford Highway, Atlanta, GA 30341, Telephone: 770-488-3300; email 
address [email protected].

SUPPLEMENTARY INFORMATION: 
    Purpose: The Lead Exposure and Prevention Advisory Committee was 
established under Section 2203 of Public Law 114-322, the Water 
Infrastructure Improvements for the Nation Act; 42 U.S.C. 300j-27, 
Registry for Lead Exposure and Advisory Committee. The Secretary, 
Department of Health and Human Services (HHS) and by delegation, the 
Director, CDC and Administrator, NCEH/ATSDR, are authorized under 
Section 2203 of Public Law 114-322 (42 U.S.C. 300j-27) to review 
research and Federal programs and services related to lead poisoning 
and to identify effective services and best practices for addressing 
and preventing lead exposure in communities.
    The LEPAC is charged with providing advice and guidance to the 
Secretary, HHS, and the Director, CDC and Administrator, ATSDR, on the: 
(1) Review of Federal programs and services available to individual 
communities exposed to lead; (2) review current research on lead 
exposure to identify additional research needs; (3) review and identify 
best practices, or the need for best practices regarding lead screening 
and the prevention of lead poisoning; (4) identify effective services, 
including services relating to healthcare, education, and nutrition for 
individuals and communities affected by lead exposure and lead 
poisoning, including in consultation with, as appropriate, the lead 
exposure registry as established in Section 2203(b) of Public Law 114-
322; and (5) undertake any other review or activities that the 
Secretary determines to be appropriate.
    Matters To Be Considered: The agenda will include discussions on 
the 2018 Federal Lead Action Plan; COVID-19 and CDC lead surveillance, 
lead laboratory methods; U.S. Housing and Urban Development's (HUD) 
role in lead poisoning prevention; an update from CDC's blood lead 
reference value workgroup; and a discussion on effective services and 
best practices regarding lead screening and lead poisoning prevention 
and research gaps. Agenda items are subject to change as priorities 
dictate. The Director, Strategic Business Initiatives Unit, Office of 
the Chief Operating Officer, Centers for Disease Control and 
Prevention, has been delegated the authority to sign Federal Register 
notices pertaining to announcements of meetings and other committee 
management activities, for both the Centers for Disease Control and 
Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief 
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2020-18161 Filed 8-18-20; 8:45 am]
BILLING CODE 4163-18-P